[1] 黄麟，杨作成. 川崎病发病机制的研究进展 [J]. 中华儿科杂志，2009，47(4): 265-267. [2] Natividad MF，Torres-Villanueva CA，Saloma CP. Superantigen involvement and susceptibility factors in Kawasaki disease: profiles of TCR Vβ2+ T cells and HLA-DRB1，TNF-α and ITPKC genes among Filipino patients [J]. Int J Mol Epidemiol Genet，2013，4(1):70-76. [3] Takahashi K，Oharaseki T，Yokouchi Y. Pathogenesis of Kawasaki disease [J]. Clin Exp Immunol，2011，164(Suppl 1): 20-22. [4] 罗建平，龚方威. 川崎病并发冠状动脉研究进展 [J]. 国际儿科学杂志，2012，39(2): 135-137. [5] Lee EJ，Park YW，Hong YM，et al. Epidemiology of Kawasaki disease in infants 3 months of age and younger [J]. Korean J Pediatr，2012，55(6): 202-205. [6] Lee G，Lee SE，Hong YM，et al. Is high-dose aspirin necessary in the acute phase of Kawasaki disease? [J]. Korean Circ J，2013，43(3): 182-186. [7] Burns JC，Herzog L，Fabri O，et al. Seasonality of Kawasaki disease: a global perspective [J]. PLoS One，2013，8(9): e74529. [8] Inciarte-Mundo J，Hernández MV，Rosario V，et al. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions [J]. Reumatol Clin，2014，10(1): 10-16. [9] Lima HC，Kimball AB. Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis [J]. Indian J Dermatol，2010，55(2): 171-175. [10] 周炯，郑敏. 新型生物制剂在关节病型银屑病中的应用 [J]. 浙江大学学报: 医学版，2009，38(4): 404-408. [11] Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept，infli-ximab and adalimumab [J] . J Dermatolog Treat，2004，15( 5) : 280-294. [12] Imrie FR，Dick AD. Biologics in the treatment of uveitis [J]. Curr Opin Ophthamlol，2007，18 ( 6): 481-486. [13] Kuo HC，Yu HR，Wu CC，et al. Etanercept treatment for children with refractory juvenile idiopathic arthritis [J]. J Microbiol Immunol Infect，2011，44(1): 52-56. [14] Muta H，Ishii M，Egami K，et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan [J]. J Pediatr，2004，144(4) : 496-499． [15] Fukuda S，Ito S，Oana S，et al. Late development of coronary artery abnormalities could be associated with persistence of non-fever symptoms in Kawasaki disease [J]. Pediatr Rheumatol Online J，2013，11(1):28. [16] Yeo JS，Choi JW. Effectiveness of medium-dose intravenous immunoglobulin (1 g /kg) in the treatment of Kawasaki disease [J]. Korean Circ J，2010，40(2): 81-85. [17] Inoue Y，Okada Y，Shinohara M，et al．A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome [J]. J Pediatr，2006，149(3): 336-341. [18] Song MS，Lee SB，Sohn S，et al. Infliximab treatment for refractory Kawasaki disease in Korean children [J]. Korean Circ J，2010，40(7): 334-338. [19] Newburger JW，Sleeper LA，McCrindle BW，et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease [J]. N Engl J Med，2007，356(7): 663-675. [20] Son MB，Gauvreau K，Burns JC，et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study [J]. J Pediatr，2011，158(4): 644-649. [21] Choueiter NF，Olson AK，Shen DD，et al. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease [J]. J Pediatr，2010，157(6): 960-966. [22] Portman MA，Olson A，Soriano B，et al. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale [J]. Am Heart J，2011，161(3): 494-499. [23] Ohashi R，Fukazawa R，Watanabe M，et al. Etanercept suppresses arteritis in a murine model of Kawasaki disease: a comparative study involving different biological agents [J]. Int J Vasc Med，2013，2013: 543141. [24] Mertens M，Singh JA. Anakinra for rheumatoid arthritis: a systematic review [J]. J Rheumatol，2009，36(6): 1118-1125. [25] Abbate A，Salloum FN，Vecile E，et al. Anakinra，a recombinant human interleukin-1 receptor antagonist，inhibits apoptosis in experimental acute myocardial infarction [J]. Circulation，2008，117(20): 2670-2683. [26] Lee Y，Schulte DJ，Shimada K，et al. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease [J]. Circulation，2012，125(12): 1542-1550. [27] Pescovitz MD，Greenbaum CJ，Krause-Steinrauf H，et al. Rituximab，B- lymphocyte depletion，and preservation of beta-cell function [J]. N Engl J Med，2009，361(22): 2143-2152. [28] Eleftheriou D，Melo M，Marks SD，et al. Biologic therapy in primary systemic vasculitis of the young [J]. Rheumatology (Oxford)，2009，48(8): 978-986. [29] Benucci M，Saviola G，Manfredi M，et al. Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis [J]. Biologics，2013，7: 69-75. [30] Sauvaget E，Bonello B，David M，et al. Resistant Kawasaki disease treated with anti-CD20 [J]. J Pediatr，2012，160(5): 875-876 . [31] Athappan G，Gale S，Ponniah T. Corticosteroid therapy for primary treatment of Kawasaki disease-weight of evidence: a meta-analysis and systematic review of the literature [J]. Cardiovasc J Afr，2009，20(4): 233-236. [32] Chen YT，Liao WL，Lin YJ，et al. Association between SRC-1 gene polymorphisms and coronary artery aneurysms formation in Taiwa-nese children with Kawasaki disease [J]. J Clin Lab Anal，2014，Mar 20.doi：10.1002/jcla.21706. [33] Tembhare PR，Marti G，Wiestner A，et al. Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia [J]. Am J Clin Pathol，2013，140(6): 813-818. [34] Johnson PN，Kuhn RJ. Combination thrombolytic and anti-platelet therapies in an infant with incomplete Kawasaki disease and coronary aneurysms [J]. J Pediatr Pharmacol Ther，2008，13(4): 242-250. [35] Gedalia A. Kawasaki disease: 40 years after the original report [J]. Curr Rheumatol Rep，2007，9(4): 336-341． [36] Gavin PJ，Crawford SE，Shulman ST，et al. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease [J]. Arterioscler Thromb Vasc Biol，2003，23(4): 576-581.
